SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Opko Health Inc (OPK)

OPK RSS Feed
Add OPK Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 8/17/2017 11:14:30 PM - Followers: 164 - Board type: Free - Posts Today: 0

Opko Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD Wednesday July 11, 8:00 am ET -Trial Designed to Compare Efficacy of Bevasiranib Administered Every 8 Weeks or 12 Weeks with Lucentis(R) Administered Every 4 Weeks- -Represents First-Ever Phase 3 Pivotal Trial of an RNAi Therapeutic- MIAMI, July 11 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced the initiation of the Phase 3 COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (wet AMD.) The multi-national COBALT study is currently open and enrolling patients. The trial will include more than 330 wet AMD patients and will assess whether bevasiranib administered every 8 or 12 weeks is safe and has equivalent efficacy in preventing vision loss as Genentech's Lucentis® administered every four weeks. ADVERTISEMENT Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF), believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase 3 clinical trials. "This first-ever Phase 3 trial of an agent based on RNAi technology is an important milestone in this new field. We are proud of the ability demonstrated by our clinical group to have successfully moved this innovative compound through development rapidly and cost effectively," said Philip Frost, M.D., Chairman and CEO of Opko Health. "Currently patients with wet AMD undergo intravitreal injections every four weeks to achieve the vision- preserving benefits of Lucentis, so the potential ability of bevasiranib to achieve similar results while requiring less frequent injections would be an important benefit for these patients who often have limited mobility." "Bevasiranib's demonstrated safety profile, its ability to inhibit the growth of the retinal lesions associated with wet AMD and its potential for prolonged duration are a promising foundation for this pivotal trial," said Lawrence Singerman M.D., founder and Executive Secretary of the Macula Society, Clinical Professor of Ophthalmology at Case University and a Principal Investigator for the Phase 3 study. "Bevasiranib's potential to serve as a long-term maintenance therapy for wet AMD could provide important benefits to patients, and I look forward to helping to assess its utility in this groundbreaking study." "We are very pleased at the enthusiastic reception the COBALT trial has received from retinal centers around the globe," said Denis O'Shaughnessy, Ph.D., Senior Vice President of Clinical Development at Opko. "Retinal physicians are keenly aware of the burden that frequent drug injections places on elderly patients and their families, and they are eager to help test an innovative new approach that has the potential to significantly reduce that burden while preserving patients' vision." About Wet AMD Wet age-related macular degeneration is the leading cause of irreversible vision loss in the developed world and its incidence is growing rapidly. Advanced age is the main risk factor for wet AMD, and it is expected to become an increasingly common condition as the population grows older. An estimated 1.65 million Americans have wet AMD today and an estimated 11 million people worldwide will have AMD by 2013. Until recently, treatments for wet AMD were of limited efficacy. In the search for more effective treatments, researchers targeted VEGF, shown to be a key cause of the excess growth and leakiness of ocular blood vessels that result in loss of vision in these patients. Current VEGF antagonists, such as Lucentis, slow this vision loss, but require injections into the eye every four weeks, a particular issue for elderly patients who often have limited mobility. Opko Health, Inc. Announces Early Termination of Hart-Scott-Rodino Waiting Period for Proposed Purchase of Shares by Dr. Phillip Frost Thursday July 12, 8:00 am ET MIAMI July 12 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced that that the U.S. Department of Justice has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the potential acquisition of additional shares of Opko Health common stock by Dr. Phillip Frost, CEO and Chairman of Opko. Dr. Frost has requested clearance to purchase additional shares of Opko Health common stock, which this action by the Justice Department now makes feasible.
OPK
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OPK News: Current Report Filing (8-k) 08/17/2017 08:32:34 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 08/17/2017 07:20:02 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 08/16/2017 07:19:10 AM
OPK News: Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update 08/15/2017 08:05:00 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 08/15/2017 07:06:38 AM
News News Alert: Current Report Filing (8-k) 08/17/2017 08:32:34 AM
PostSubject
#5522   It's ok I am in no rush. Yes this Juice555 08/17/17 11:14:30 PM
#5521   Yea probably a little more than that. At game7alcs 08/17/17 11:01:32 PM
#5520   lol So he owns about 30 percent of the Juice555 08/17/17 11:00:09 PM
#5519   I think he is around 165,000,000 shares at game7alcs 08/17/17 10:59:30 PM
#5518   You probably know this and will save me Juice555 08/17/17 10:53:32 PM
#5517   I gave up on motives in this business game7alcs 08/17/17 10:39:00 PM
#5516   What's wrong with these analyst it's almost like Juice555 08/17/17 07:11:14 PM
#5515   Nice! I'm thinking we might have a little game7alcs 08/17/17 05:09:32 PM
#5514   I believe that the lower the stock price surgeon_general 08/17/17 04:55:48 PM
#5513   I bought 2k at 5.90 Juice555 08/17/17 04:25:18 PM
#5512   I'm buying in the morning game7alcs 08/17/17 04:17:52 PM
#5511   I'm with you on that. game7alcs 08/17/17 12:21:42 PM
#5510   I am waiting for a bounce in TEVA Juice555 08/17/17 12:18:14 PM
#5509   I think that's as good of a bet game7alcs 08/17/17 11:43:50 AM
#5508   I added a few thousand shares recently Sky10 08/17/17 11:42:10 AM
#5507   I agree. They seem to be very cautious game7alcs 08/17/17 11:09:57 AM
#5506   Not the PR I am expecting So much potential Juice555 08/17/17 10:49:03 AM
#5505   • Opko Health (OPK +0.8%) has signed a game7alcs 08/17/17 10:42:47 AM
#5504   reread my message... still have Thousands of shares terry hallinan 08/11/17 03:30:02 PM
#5503   WHAT?? Didn't wait?? Ah... reread my now invest 08/11/17 11:47:44 AM
#5502   Investing in stock markets always carries risks but Sky10 08/11/17 11:22:26 AM
#5501   "FIRST TIME... IN YEARS... ANOTHER DRUG COMPANY IS terry hallinan 08/10/17 02:35:07 PM
#5500   Well had money to invest... but didn't now invest 08/10/17 11:59:43 AM
#5499   https://www.cnbc.com/video/2017/08/09/biotech-ceo-new-prostate-test-will-revolut joe_techi 08/09/17 08:25:50 PM
#5498   Frost wouldn't comment on the stock price!!! now invest 08/09/17 07:29:27 PM
#5497   Exactly And we all know frost is very well connected Juice555 08/09/17 03:11:44 PM
#5496   Their pipeline seems robust and diverse. Would seem joe_techi 08/09/17 02:54:37 PM
#5495   Oh it will game7alcs 08/09/17 02:40:30 PM
#5494   Waiting is not a problem Been here since 2009 Juice555 08/09/17 02:39:24 PM
#5493   Yea I don't think you can lose at game7alcs 08/09/17 02:37:41 PM
#5492   Like Dr. Frost , I have a very Sky10 08/09/17 11:40:01 AM
#5491   Don't have to tell me twice. Lol I picked Juice555 08/09/17 10:44:07 AM
#5490   That's good. I'm sure he will just regurgitate game7alcs 08/09/17 10:23:14 AM
#5489   On CNBC's Squawk on the Street this AM, barnstormer 08/09/17 10:05:54 AM
#5487   WHAT USE BRLI'S SALES TEAM???? They now invest 08/09/17 09:25:17 AM
#5486   MY SUMMARY OF FROST'S AND OTHERS COMMENTS... now invest 08/09/17 09:23:58 AM
#5485   Same as it ever was joe_techi 08/08/17 05:18:04 PM
#5484   OPKO Q2 top line off 12%; earnings down joe_techi 08/08/17 05:13:00 PM
#5483   Should see $5d tomorrow like I stated. game7alcs 08/08/17 04:57:26 PM
#5482   Yawn...it would seem joe_techi 08/08/17 04:28:39 PM
#5481   Yea very possibly another uneventful nothing new call. game7alcs 08/08/17 03:39:00 PM
#5480   Well at least we have low expectations Lol Juice555 08/08/17 02:44:52 PM
#5479   WONDER WHAT DELAYS.... OR FAILURES... OR DISSAPOINTMENTS now invest 08/08/17 01:27:59 PM
#5478   My guess is there might be an opportunity game7alcs 08/06/17 09:02:39 AM
#5477   Good post! This company most likely won't Fangster 08/05/17 02:09:49 PM
#5476   I don't blame you. I didn't realize you game7alcs 08/03/17 04:59:01 PM
#5475   I own a bunch of this long and joe_techi 08/03/17 03:12:04 PM
#5474   in my opinion , at $6/sh OPK has Sky10 08/03/17 12:10:33 PM
#5473   I agree with your points more and more game7alcs 08/03/17 10:16:40 AM
#5472   unfortunately their IR dont exist. I've tried emailing knightz33 08/03/17 10:13:01 AM
PostSubject